TSX:IN

Stock Analysis Report

Executive Summary

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has InMed Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.9%

IN

0.6%

CA Biotechs

0.1%

CA Market


1 Year Return

-61.6%

IN

-18.5%

CA Biotechs

1.6%

CA Market

Return vs Industry: IN underperformed the Canadian Biotechs industry which returned -18.5% over the past year.

Return vs Market: IN underperformed the Canadian Market which returned 1.6% over the past year.


Shareholder returns

INIndustryMarket
7 Day-1.9%0.6%0.1%
30 Day-19.7%-13.9%-2.9%
90 Day-18.5%-17.0%-1.4%
1 Year-61.6%-61.6%-18.5%-18.5%5.2%1.6%
3 Year60.6%60.6%-17.7%-17.7%13.8%3.7%
5 Yearn/a13.5%13.5%25.3%7.2%

Price Volatility Vs. Market

How volatile is InMed Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InMed Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate IN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate IN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IN is good value based on its PB Ratio (2.5x) compared to the CA Biotechs industry average (3.5x).


Next Steps

Future Growth

How is InMed Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IN's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if IN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if IN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has InMed Pharmaceuticals performed over the past 5 years?

-36.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IN is unprofitable, and losses have increased over the past 5 years at a rate of -36.2% per year.

Accelerating Growth: Unable to compare IN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: IN has a negative Return on Equity (-72.73%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is InMed Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: IN's short term assets (CA$18.5M) exceeds its short term liabilities (CA$1.6M)

Long Term Liabilities: IN has no long term liabilities


Debt to Equity History and Analysis

Debt Level: IN is debt free.

Reducing Debt: IN has no debt compared to 5 years ago when its debt to equity ratio was 0.08%.


Balance Sheet

Inventory Level: IN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IN has sufficient cash runway for 1.408979 years if free cash flow continues to reduce at historical rates of -63% each year.


Next Steps

Dividend

What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of InMed Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Eric Adams (55yo)

3.3yrs

Tenure

CA$2,574,950

Compensation

Mr. Eric A. Adams, B.S. Chem., M.I.B. has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Eric's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.0yrs

Average Tenure

Experienced Management: IN's management team is considered experienced (3 years average tenure).


Board Age and Tenure

1.7yrs

Average Tenure

55.5yo

Average Age

Experienced Board: IN's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: IN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$3,82513 Oct 19
Alexandra D. Mancini
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Clinical & Regulatory Affairs
Shares15,000
Max PriceCA$0.26
BuyCA$3,93911 Oct 19
Bruce Colwill
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares15,000
Max PriceCA$0.26
BuyCA$3,90010 Oct 19
Alexandra D. Mancini
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Clinical & Regulatory Affairs
Shares15,000
Max PriceCA$0.26
BuyCA$19,41109 Oct 19
Alexandra D. Mancini
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Clinical & Regulatory Affairs
Shares70,000
Max PriceCA$0.28
BuyCA$1,40004 Oct 19
Bruce Colwill
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceCA$0.28
BuyCA$14,74210 Jul 19
Eric Hsu
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Preclinical Research & Development
Shares42,000
Max PriceCA$0.35
BuyCA$6,44004 Jul 19
Michael Woudenberg
EntityIndividual
Shares17,500
Max PriceCA$0.37
BuyCA$34,78003 Jul 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares100,000
Max PriceCA$0.35
BuyCA$20,06418 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares40,000
Max PriceCA$0.50
BuyCA$4,91716 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares10,500
Max PriceCA$0.47
BuyCA$24,18015 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares50,000
Max PriceCA$0.48

Ownership Breakdown


Management Team

  • Bruce Colwill

    Chief Financial Officer

    • Tenure: 0.2yrs
  • Alexandra D. Mancini

    Senior Vice President of Clinical & Regulatory Affairs

    • Tenure: 3yrs
    • Compensation: CA$692.50k
  • Jeff Charpentier

    VP of Finance & Corporate Secretary

    • Tenure: 2.8yrs
    • Compensation: CA$737.65k
  • Paul Brennan

    Strategic Advisor

    • Tenure: 3.4yrs
  • Eric Adams (55yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CA$2.57m
  • Richard Hoy

    Vice President of Sales & Marketing

    • Tenure: 15.1yrs
  • Eric Hsu

    Senior Vice President of Preclinical Research & Development

    • Tenure: 0.8yrs
    • Compensation: CA$854.58k
  • Sazzad Hossain

    Co-Founder & Member of the Scientific Advisory Board

    • Tenure: 0.8yrs
    • Compensation: CA$184.70k
  • Ado Muhammad

    Senior Consultant of Medical affairs

    • Tenure: 0yrs

Board Members

  • Steven Dinh (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0.6yrs
  • Eric Adams (55yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CA$2.57m
  • Bill Garner (53yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: CA$21.62k
  • Andy Hull (56yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: CA$13.31k
  • Adam Cutler (45yo)

    Director

    • Tenure: 3.9yrs
    • Compensation: CA$13.31k
  • Sazzad Hossain

    Co-Founder & Member of the Scientific Advisory Board

    • Tenure: 0.8yrs
    • Compensation: CA$184.70k
  • Catherine Sazdanoff (63yo)

    Director

    • Tenure: 0.3yrs
  • Mauro Maccarrone

    Member of Scientific Advisory Board

    • Tenure: 2yrs
  • Vikramaditya Yadav

    Member of Scientific Advisory Board

    • Tenure: 1.4yrs

Company Information

InMed Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InMed Pharmaceuticals Inc.
  • Ticker: IN
  • Exchange: TSX
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$45.655m
  • Shares outstanding: 172.28m
  • Website: https://www.inmedpharma.com

Number of Employees


Location

  • InMed Pharmaceuticals Inc.
  • 200 Granville Street
  • Suite 340
  • Vancouver
  • British Columbia
  • V6C 1S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INTSX (The Toronto Stock Exchange)YesCommon SharesCACADAug 1999
MWG2DB (Deutsche Boerse AG)YesCommon SharesDEEURAug 1999
IMLF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDAug 1999

Biography

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candida ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:40
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.